Regenicin (OTCMKTS:RGIN) versus Inspire Medical Systems (NYSE:INSP) Head to Head Contrast

Inspire Medical Systems (NYSE:INSP) and Regenicin (OTCMKTS:RGIN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Earnings and Valuation

This table compares Inspire Medical Systems and Regenicin”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$624.80 million	9.45	-$21.15 million	$1.07	185.14
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A

Regenicin has lower revenue, but higher earnings than Inspire Medical Systems.

Profitability

This table compares Inspire Medical Systems and Regenicin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	4.37%	5.51%	4.74%
Regenicin	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for Inspire Medical Systems and Regenicin, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	0	4	8	0	2.67
Regenicin	0	0	0	0	0.00

Inspire Medical Systems currently has a consensus price target of $227.75, indicating a potential upside of 14.97%. Given Inspire Medical Systems’ stronger consensus rating and higher probable upside, equities analysts clearly believe Inspire Medical Systems is more favorable than Regenicin.

Risk and Volatility

Inspire Medical Systems has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Regenicin has a beta of -18.99, suggesting that its share price is 1,999% less volatile than the S&P 500.

Institutional & Insider Ownership

94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 0.0% of Regenicin shares are owned by institutional investors. 4.1% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Inspire Medical Systems beats Regenicin on 10 of the 11 factors compared between the two stocks.

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.